---
document_datetime: 2023-09-21 19:14:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/humenza-epar-all-authorised-presentations_en.pdf
document_name: humenza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.3899354
conversion_datetime: 2025-12-18 21:11:16.961377
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## EU Number

EU/1/10/629/001

-1-

3.8 Âµg HA

After mixing, 1 dose (0.5 ml) contains:

Split Influenza virus, inactivated, containing antigen* equivalent to:

A/California/7/2009 (H1N1)-like strain (NYMC X-179A)

* propagated in eggs

** haemagglutinin

AF03 adjuvant composed of squalene (12.4 milligrams), sorbitan oleate (1.9 milligrams), polyoxyethylene cetostearyl ether (2.4 milligrams) and mannitol (2.3 milligrams)

Strength

-1-

Route of

Administration

Intramuscular use

Packaging

Emulsion (adjuvant):

vial (glass)

Content

Suspension: 1.5 ml

Emulsion: 4.5 ml

Medicinal product no longer authorised Invented name Pharmaceutical Form HUMENZA Suspension and emulsion for emulsion for injection Suspension (H1N1): vial (glass); 3.8 micrograms HA**

## Package size

10 vials (suspension)

+

10 vials (emulsion)